Douglas Tremblay

686 total citations
20 papers, 328 citations indexed

About

Douglas Tremblay is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Douglas Tremblay has authored 20 papers receiving a total of 328 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 12 papers in Genetics and 7 papers in Molecular Biology. Recurrent topics in Douglas Tremblay's work include Acute Myeloid Leukemia Research (10 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Douglas Tremblay is often cited by papers focused on Acute Myeloid Leukemia Research (10 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Douglas Tremblay collaborates with scholars based in United States. Douglas Tremblay's co-authors include John Mascarenhas, Leonard Naymagon, Nicole A. Carreau, Ronald Hoffman, Mohamed E. Salama, Srđan Verstovšek, Santiago Thibaud, Jonathan Feld, Alaina J. Kessler and Marina Kremyanskaya and has published in prestigious journals such as JAMA, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Douglas Tremblay

20 papers receiving 326 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Douglas Tremblay United States 10 190 179 88 71 65 20 328
Javier Garcés‐Eisele Mexico 12 285 1.5× 115 0.6× 78 0.9× 58 0.8× 61 0.9× 37 424
Natalia Curto‐García United Kingdom 9 116 0.6× 147 0.8× 72 0.8× 28 0.4× 77 1.2× 23 239
Woo‐Sung Min South Korea 14 323 1.7× 119 0.7× 87 1.0× 26 0.4× 26 0.4× 34 451
Joycelyn Sim China 9 199 1.0× 117 0.7× 100 1.1× 25 0.4× 41 0.6× 19 292
Nicola Orofino Italy 10 173 0.9× 151 0.8× 64 0.7× 22 0.3× 48 0.7× 22 266
Ambra Di Veroli Italy 13 228 1.2× 118 0.7× 86 1.0× 16 0.2× 28 0.4× 31 340
Artit Ungkanont Thailand 15 263 1.4× 229 1.3× 62 0.7× 29 0.4× 12 0.2× 28 447
Rebecca Howman Australia 9 132 0.7× 63 0.4× 102 1.2× 25 0.4× 25 0.4× 15 289
Dan Xu China 11 168 0.9× 73 0.4× 41 0.5× 18 0.3× 43 0.7× 43 264
Alessandra Cupri Italy 11 214 1.1× 88 0.5× 67 0.8× 10 0.1× 33 0.5× 27 313

Countries citing papers authored by Douglas Tremblay

Since Specialization
Citations

This map shows the geographic impact of Douglas Tremblay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas Tremblay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas Tremblay more than expected).

Fields of papers citing papers by Douglas Tremblay

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas Tremblay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas Tremblay. The network helps show where Douglas Tremblay may publish in the future.

Co-authorship network of co-authors of Douglas Tremblay

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas Tremblay. A scholar is included among the top collaborators of Douglas Tremblay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas Tremblay. Douglas Tremblay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sastow, Dahniel, et al.. (2025). Contemporary CMML Risk Stratification and Management. Current Hematologic Malignancy Reports. 20(1). 8–8. 1 indexed citations
2.
Toh, Jennifer, et al.. (2025). The evaluation, management, and future of indolent systemic mastocytosis. Annals of Hematology. 104(8). 3917–3927. 1 indexed citations
3.
Sastow, Dahniel, et al.. (2024). Ven the dose matters: Venetoclax dosing in the frontline treatment of AML. Blood Reviews. 68. 101238–101238. 2 indexed citations
4.
Tremblay, Douglas, et al.. (2024). Diagnosis and Treatment of Polycythemia Vera. JAMA. 333(2). 153–153. 4 indexed citations
5.
Handa, Shivani, Andrew Srisuwananukorn, Amylou C. Dueck, et al.. (2024). Oral Decitabine/Cedazuridine Is an Effective Ambulatory Therapy for Patients With Myelofibrosis Refractory to JAK2 Inhibitor Therapy. Clinical Lymphoma Myeloma & Leukemia. 24(9). e314–e319. 2 indexed citations
6.
Sastow, Dahniel, et al.. (2024). Estimating the Prevalence of Possible Undiagnosed Chronic Myelomonocytic Leukemia in the General Population: An Nhanes Analysis. Blood. 144(Supplement 1). 5182–5182. 1 indexed citations
7.
Dubin, Danielle P., et al.. (2023). Dasatinib-Associated Acneiform Eruption Successfully Treated With Sarecycline in a Patient With Chronic Myeloid Leukemia. Cureus. 15(9). e45697–e45697. 1 indexed citations
8.
Tremblay, Douglas, Joseph Rapp, Naomi Alpert, et al.. (2021). Mild anemia as a single independent predictor of mortality in patients with COVID‐19. SHILAP Revista de lepidopterología. 2(3). 319–326. 13 indexed citations
9.
Tremblay, Douglas, Naomi Alpert, Emanuela Taioli, & John Mascarenhas. (2021). Prevalence of unexplained erythrocytosis and thrombocytosis – an NHANES analysis. Leukemia & lymphoma. 62(8). 2030–2033. 5 indexed citations
10.
Feld, Jonathan, Douglas Tremblay, Santiago Thibaud, Alaina J. Kessler, & Leonard Naymagon. (2020). Ferritin levels in patients with COVID‐19: A poor predictor of mortality and hemophagocytic lymphohistiocytosis. International Journal of Laboratory Hematology. 42(6). 773–779. 48 indexed citations
11.
Naymagon, Leonard, Douglas Tremblay, & John Mascarenhas. (2020). Reevaluating the role of ferritin in the diagnosis of adult secondary hemophagocytic lymphohistiocytosis. European Journal Of Haematology. 104(4). 344–351. 22 indexed citations
12.
Tremblay, Douglas, Amber C. King, Lihua Li, et al.. (2019). Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis. Leukemia & lymphoma. 61(3). 660–667. 20 indexed citations
13.
Naymagon, Leonard, Erin Moshier, Douglas Tremblay, & John Mascarenhas. (2019). Predictors of early hemorrhage in acute promyelocytic leukemia. Leukemia & lymphoma. 60(10). 2394–2403. 23 indexed citations
14.
Tremblay, Douglas & John Mascarenhas. (2018). Pacritinib to treat myelofibrosis patients with thrombocytopenia. Expert Review of Hematology. 11(9). 707–714. 10 indexed citations
15.
Choi, Daniel, Douglas Tremblay, Camelia Iancu‐Rubin, & John Mascarenhas. (2017). Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms. Annals of Hematology. 96(6). 919–927. 17 indexed citations
16.
Carreau, Nicole A., Douglas Tremblay, Michael R. Savona, Marina Kremyanskaya, & John Mascarenhas. (2016). Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes. Blood Reviews. 30(5). 349–356. 17 indexed citations
17.
Bhalla, Sheena, Douglas Tremblay, & John Mascarenhas. (2016). Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions. Clinical Lymphoma Myeloma & Leukemia. 16(9). 488–494. 8 indexed citations
18.
Tremblay, Douglas, Julia H. Arnsten, & William N. Southern. (2016). A Simple and Powerful Risk-Adjustment Tool for 30-day Mortality Among Inpatients. Quality Management in Health Care. 25(3). 123–128. 2 indexed citations
19.
Salama, Mohamed E., Nicole A. Carreau, Douglas Tremblay, et al.. (2016). Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies. Haematologica. 101(6). 660–671. 119 indexed citations
20.
Tremblay, Douglas, Nicole A. Carreau, Marina Kremyanskaya, & John Mascarenhas. (2015). Systemic Mastocytosis: Clinical Update and Future Directions. Clinical Lymphoma Myeloma & Leukemia. 15(12). 728–738. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Javier Garcés‐Eisele Breakdown of academic impact, for papers by Natalia Curto‐García Breakdown of academic impact, for papers by Woo‐Sung Min Breakdown of academic impact, for papers by Joycelyn Sim Breakdown of academic impact, for papers by Nicola Orofino Breakdown of academic impact, for papers by Ambra Di Veroli Breakdown of academic impact, for papers by Artit Ungkanont Breakdown of academic impact, for papers by Rebecca Howman Breakdown of academic impact, for papers by Dan Xu Breakdown of academic impact, for papers by Alessandra Cupri
Rankless by CCL
2026